BOLT

Bolt is a pre-commercial immuno-oncology developer, not an operating business: the entire $7.70M of FY2025 'revenue' is flat collaboration income (+0.1% YoY, and essentially unchanged since FY2023's $7.88M), while the company runs a -469.3% operating margin and a -433.7% net margin. The FY2025 net loss of -$33.4M looks 'improved' (+47.1% YoY) only because management is retrenching — R&D was cut in half to $28.5M (-50.4%) and total assets fell 43% to $56.7M. This is a company shrinking to survive, not scaling. The 10-K's own risk summary is explicit: 'a limited operating history,' 'significant losses since inception,' anticipation of continued losses 'for the foreseeable future,' and that it 'may never achieve or maintain profitability' and 'will need substantial funding.'

The balance sheet is the binding constraint. Cash of $11.7M against operating cash burn of -$39.9M implies well under a year of runway even after the R&D cuts. Stockholders' equity collapsed 53.7% to $26.5M, liabilities/equity sits at 1.14x, and the accumulated deficit is -$461M — this enterprise has consumed nearly half a billion dollars and has no self-funding path. The 95% YoY drop in share count to 1.92M reflects a large reverse split, a classic signal of a stock fighting delisting. Absent a new raise, partnership, or reverse merger, dilution or wind-down is the base case.